tiprankstipranks
Trending News
More News >
Humana AB (SE:HUM)
:HUM
Advertisement

Humana AB (HUM) AI Stock Analysis

Compare
2 Followers

Top Page

SE:HUM

Humana AB

(Frankfurt:HUM)

Rating:70Neutral
Price Target:
kr41.00
▲(1.11% Upside)
Humana AB's overall score is driven by stable financial performance and attractive valuation. The company's strong cash flow and efficient cost management are significant strengths, while high leverage and declining revenue growth are notable risks. Technical indicators suggest a positive short-term outlook, supporting the stock's potential for appreciation.

Humana AB (HUM) vs. iShares MSCI Sweden ETF (EWD)

Humana AB Business Overview & Revenue Model

Company DescriptionHumana AB (publ) provides individual and family care services for children and adults in Sweden, Finland, Norway, and Denmark. It operates through five segments: Individual & Family, Personal Assistance, Elderly Care, Finland, and Norway segments. The Individual & Family segment provides care and treatment for psychosocial disorders, mental illness, and functional impairment; residential care homes; interim and regular family-based care services; special service housing; outpatient care services; assisted living homes; and specially adapted housing for individuals with functional impairments and special education schools. The Personal Assistance segment offers care services and assistance to individuals with functional impairments. The Elderly Care segment provides elderly care home services. The Finland segment offers individual and family care for children, young people and families with psychiatric diagnoses or psychosocial disorders; special service housing for individuals with functional impairments; elderly care homes; and elderly day care services. The Norway segment provides individual and family care, personal assistance, and special service housing for individuals with functional impairments. The company was founded in 2001 and is headquartered in Stockholm, Sweden.
How the Company Makes MoneyHumana AB generates revenue primarily through the provision of care services across its key sectors: individual and family care, personal assistance, and elderly care. The company's revenue streams include government contracts, private pay clients, and partnerships with local municipalities who require outsourced care services. Additionally, Humana AB leverages its extensive network of facilities and trained staff to deliver personalized care, ensuring a steady flow of income from long-term care agreements and service fees. Strategic partnerships with healthcare providers and continuous investment in service innovation further contribute to the company's earnings.

Humana AB Financial Statement Overview

Summary
Humana AB demonstrates stable financial health with strong cash flow generation and efficient cost management. However, high leverage and declining revenue growth are areas of concern. The company should focus on improving profitability and reducing debt to enhance financial stability.
Income Statement
65
Positive
Humana AB's income statement shows mixed results. The TTM gross profit margin is strong at 34.7%, indicating efficient cost management. However, the net profit margin is low at 2.04%, suggesting limited profitability. Revenue growth has declined by 25.9% in the TTM, which is a concern. EBIT and EBITDA margins are moderate, reflecting stable operational efficiency but with room for improvement.
Balance Sheet
60
Neutral
The balance sheet reveals a high debt-to-equity ratio of 1.58, indicating significant leverage which could pose financial risks. Return on equity is modest at 6.77%, showing average profitability from shareholders' investments. The equity ratio is not explicitly calculated but suggests a balanced asset structure.
Cash Flow
70
Positive
Cash flow analysis is positive with a 19.88% growth in free cash flow, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 0.39, showing good cash conversion. The free cash flow to net income ratio of 0.85 suggests efficient cash utilization relative to earnings.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue10.39B10.29B9.65B9.20B8.19B7.77B
Gross Profit3.61B896.00M757.00M9.14B8.13B7.39B
EBITDA1.13B1.05B457.00M901.00M892.00M842.00M
Net Income212.00M144.00M176.00M210.00M276.00M262.00M
Balance Sheet
Total Assets10.01B10.63B10.03B9.81B9.00B8.04B
Cash, Cash Equivalents and Short-Term Investments645.00M583.00M675.00M690.00M695.00M759.00M
Total Debt4.87B5.15B5.02B5.40B4.92B4.27B
Total Liabilities6.78B7.33B7.10B7.07B6.45B5.69B
Stockholders Equity3.09B3.16B2.89B2.74B2.55B2.35B
Cash Flow
Free Cash Flow808.00M869.00M451.00M442.00M582.00M528.00M
Operating Cash Flow951.00M869.00M621.00M633.00M689.00M661.00M
Investing Cash Flow11.00M-532.00M-151.00M-246.00M-260.00M-37.00M
Financing Cash Flow-690.00M-434.00M-457.00M-424.00M-521.00M-667.00M

Humana AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price40.55
Price Trends
50DMA
38.36
Positive
100DMA
38.19
Positive
200DMA
38.39
Positive
Market Momentum
MACD
0.63
Positive
RSI
55.96
Neutral
STOCH
26.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:HUM, the sentiment is Positive. The current price of 40.55 is below the 20-day moving average (MA) of 40.59, above the 50-day MA of 38.36, and above the 200-day MA of 38.39, indicating a bullish trend. The MACD of 0.63 indicates Positive momentum. The RSI at 55.96 is Neutral, neither overbought nor oversold. The STOCH value of 26.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:HUM.

Humana AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
kr2.07B39.58
26.06%-6.03%
70
Neutral
kr2.10B9.876.86%2.47%6.74%75.70%
65
Neutral
kr10.31B18.67
1.74%5.75%48.97%
51
Neutral
$7.95B-0.38-43.43%2.22%22.30%-1.83%
€912.16M17.3012.76%
€178.99M-41.54%
kr1.97B
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:HUM
Humana AB
40.55
8.21
25.38%
SE:ATT
Attendo AB
69.10
21.87
46.31%
DE:6MA
Ambea AB
11.46
3.80
49.61%
DE:6XP
Xspray Pharma AB
4.38
0.22
5.29%
SE:STIL
Stille AB
228.00
12.00
5.56%
SE:CARA
Carasent AB
27.25
10.47
62.40%

Humana AB Corporate Events

Humana AB Announces Share Repurchase Plan to Strengthen Capital Structure
Jul 21, 2025

Humana AB has announced a decision to repurchase up to 1,500,000 of its own shares, as authorized by the 2025 annual general meeting. This move aims to enhance the company’s capital structure and provide flexibility for potential future acquisitions, with repurchases occurring on Nasdaq Stockholm before the 2026 annual meeting. The repurchase will be conducted in cash within the stock market price interval, and the company currently holds 1,985,273 of its own shares out of a total of 51,826,058.

The most recent analyst rating on (SE:HUM) stock is a Buy with a SEK42.00 price target. To see the full list of analyst forecasts on Humana AB stock, see the SE:HUM Stock Forecast page.

Humana AB Reports Strong Half-Year Results and Strategic Financial Moves
Jul 18, 2025

Humana AB reported its second quarter and half-year 2025 results, highlighting a net revenue of SEK 2,506 million for the quarter and SEK 5,039 million for the half-year. The company experienced a slight decline in organic growth but improved its net profit after tax and free cash flow. Significant events included a share buyback program and a new loan agreement aimed at reducing interest expenses, which positions the company for future growth and profitability.

The most recent analyst rating on (SE:HUM) stock is a Buy with a SEK50.00 price target. To see the full list of analyst forecasts on Humana AB stock, see the SE:HUM Stock Forecast page.

Humana AB Reduces Financing Costs with New Loan Agreement
Jul 14, 2025

Humana AB has signed a new long-term loan agreement to refinance existing loans, amounting to approximately SEK 2.3 billion. This new loan structure, involving a larger proportion of revolving variable credits and lower interest margins, is expected to reduce the company’s annual net interest income by SEK 35 million. The agreement, which includes options for extension and expansion, allows Humana to efficiently manage its cash flow and liquidity, reflecting a strengthened financial position. The new financing will replace the current loan, positioning Humana to continue its operations effectively.

The most recent analyst rating on (SE:HUM) stock is a Buy with a SEK42.00 price target. To see the full list of analyst forecasts on Humana AB stock, see the SE:HUM Stock Forecast page.

Humana AB Completes Share Repurchase Program
May 9, 2025

Humana AB has completed a share repurchase program, buying back a total of 985,273 shares as part of a strategy to improve its capital structure. This buy-back, conducted on Nasdaq Stockholm, reflects Humana’s commitment to optimizing shareholder value and aligns with regulatory standards, potentially impacting its market positioning and stakeholder interests.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 08, 2025